Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

NCT03644823 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped slow recruiting

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Atezolizumab
RADIATION: Radiotherapy

Sponsor

Oslo University Hospital